BIG PHARMA SPLIT CL.A

F:XN4 Germany
Market Cap
$11.23 Million
€10.94 Million EUR
Market Cap Rank
#41358 Global
#6239 in Germany
Share Price
€9.00
Change (1 day)
-0.55%
52-Week Range
€6.50 - €9.50
All Time High
€9.65
About

Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.

BIG PHARMA SPLIT CL.A (XN4) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, BIG PHARMA SPLIT CL.A (XN4) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

BIG PHARMA SPLIT CL.A - Net Assets Trend (None–None)

This chart illustrates how BIG PHARMA SPLIT CL.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for BIG PHARMA SPLIT CL.A (None–None)

The table below shows the annual net assets of BIG PHARMA SPLIT CL.A from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to BIG PHARMA SPLIT CL.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

BIG PHARMA SPLIT CL.A Competitors by Market Cap

The table below lists competitors of BIG PHARMA SPLIT CL.A ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BIG PHARMA SPLIT CL.A's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares BIG PHARMA SPLIT CL.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently BIG PHARMA SPLIT CL.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares BIG PHARMA SPLIT CL.A's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BIG PHARMA SPLIT CL.A (XN4) €- N/A N/A $86.39K
Hanna Capital Corp (04U1) $-79.29K 0.00% 0.00x $116.52K
WESTMINSTER RES (08W) $4.66 Million -31.33% 0.12x $5.16 Million
Axonics Inc (0I3) $570.14 Million -10.47% 0.16x $3.29 Billion
Global Bioenergies SA (1DK) $14.81 Million -86.04% 0.89x $369.68K
GIEAG Immobilien AG (2GI) $41.80 Million 40.21% 8.93x $15.57K
2invest AG (2INV) $82.61 Million -2.29% 0.06x $13.67 Million
PT Central Proteina Prima Tbk (4PT) $3.42 Trillion 11.74% 1.00x $6.90 Million
DGH Deutsche Grundwert Holding AG (5TR) $0.00 0.00% 0.00x $18.45K
SOFTCHOICE CORP. (90Q) $58.23 Million -19.76% 10.01x $470.36 Million
ALBA SE (ABA) $142.95 Million 5.25% 0.45x $5.10 Million